Literature DB >> 34687015

Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.

Fabio Dall'Olio1, Nadia Malagolini2.   

Abstract

Among the multiple roles played by protein glycosylation, the fine regulation of biological interactions is one of the most important. The asparagine 297 (Asn297) of IgG heavy chains is decorated by a diantennary glycan bearing a number of galactose and sialic acid residues on the branches ranging from 0 to 2. In addition, the structure can present core-linked fucose and/or a bisecting GlcNAc. In many inflammatory and autoimmune conditions, as well as in metabolic, cardiovascular, infectious, and neoplastic diseases, the IgG Asn297-linked glycan becomes less sialylated and less galactosylated, leading to increased expression of glycans terminating with GlcNAc. These conditions alter also the presence of core-fucose and bisecting GlcNAc. Importantly, similar glycomic alterations are observed in aging. The common condition, shared by the above-mentioned pathological conditions and aging, is a low-grade, chronic, asymptomatic inflammatory state which, in the case of aging, is known as inflammaging. Glycomic alterations associated with inflammatory diseases often precede disease onset and follow remission. The aberrantly glycosylated IgG glycans associated with inflammation and aging can sustain inflammation through different mechanisms, fueling a vicious loop. These include complement activation, Fcγ receptor binding, binding to lectin receptors on antigen-presenting cells, and autoantibody reactivity. The complex molecular bases of the glycomic changes associated with inflammation and aging are still poorly understood.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Glycosylation in aging; Glycosyltransferases; Hypogalactosylated antibodies; Inflammaging; Intravenous immunoglobulin

Mesh:

Substances:

Year:  2021        PMID: 34687015     DOI: 10.1007/978-3-030-76912-3_10

Source DB:  PubMed          Journal:  Exp Suppl        ISSN: 1664-431X


  255 in total

1.  Identification of a receptor required for the anti-inflammatory activity of IVIG.

Authors:  Robert M Anthony; Fredrik Wermeling; Mikael C I Karlsson; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

2.  Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Authors:  Robert M Anthony; Falk Nimmerjahn; David J Ashline; Vernon N Reinhold; James C Paulson; Jeffrey V Ravetch
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

Review 3.  Mannan binding lectin and its interaction with immunoglobulins in health and in disease.

Authors:  James N Arnold; Raymond A Dwek; Pauline M Rudd; Robert B Sim
Journal:  Immunol Lett       Date:  2006-06-12       Impact factor: 3.685

4.  Immunoglobulin G glycosylation and clinical outcome in rheumatoid arthritis during pregnancy.

Authors:  A Alavi; N Arden; T D Spector; J S Axford
Journal:  J Rheumatol       Date:  2000-06       Impact factor: 4.666

5.  Impaired binding capacity of asialyl and agalactosyl IgG to Fc gamma receptors.

Authors:  Y Adler; A Lamour; C Jamin; J F Menez; R Le Corre; Y Shoenfeld; P Youinou
Journal:  Clin Exp Rheumatol       Date:  1995 May-Jun       Impact factor: 4.473

6.  Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.

Authors:  Robert M Anthony; Toshihiko Kobayashi; Fredrik Wermeling; Jeffrey V Ravetch
Journal:  Nature       Date:  2011-06-19       Impact factor: 49.962

7.  In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

Authors:  Heike Albert; Mattias Collin; Diana Dudziak; Jeffrey V Ravetch; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

8.  Changes in normal glycosylation mechanisms in autoimmune rheumatic disease.

Authors:  J S Axford; N Sumar; A Alavi; D A Isenberg; A Young; K B Bodman; I M Roitt
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

Review 9.  Beta 1,4-galactosyltransferase variations in rheumatoid arthritis.

Authors:  A Alavi; J Axford
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

10.  Reduced B-cell galactosyltransferase activity in rheumatoid arthritis.

Authors:  J S Axford; L Mackenzie; P M Lydyard; F C Hay; D A Isenberg; I M Roitt
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

View more
  1 in total

1.  Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood.

Authors:  Clizia Chinello; Noortje de Haan; Giulia Capitoli; Barbara Trezzi; Antonella Radice; Lisa Pagani; Lucrezia Criscuolo; Stefano Signorini; Stefania Galimberti; Renato Alberto Sinico; Manfred Wuhrer; Fulvio Magni
Journal:  Int J Mol Sci       Date:  2022-04-23       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.